Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization for Hympavzi (marstacimab) to ...

The drug is administered subcutaneously ... investigating treatments for people living with hemophilia. In April, the FDA ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine ...

“Today’s approval of Hympavzi provides patients with hemophilia a new treatment ... The FDA granted Hympavzi Orphan Drug designation for this application. The FDA granted the approval of Hympavzi to ...

Pfizer has won European ... Union for people with severe hemophilia B and the first to be administered via a pre-filled pen or syringe for those with severe hemophilia A or B. The U.S. Food and Drug ...

Centessa had recently conducted an interim analysis of a phase 2 study of its drug ... regulatory wins for Pfizer. First, the Big Pharma scored an FDA approval for its hemophilia B gene therapy ...

Based on these results, the FDA approved this drug for a similar indication ... decision marks the second EC approval for Pfizer this year in the hemophilia space. Earlier in July, the FDA ...